HOME >> MEDICINE >> NEWS
NIAID releases MDR/XDR Tuberculosis research agenda

WHAT: The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), today released its NIAID Research Agenda for Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB). While focusing on MDR/XDR TB, many of the research priorities identified in this document also relate to drug-sensitive tuberculosis. The research priorities identified in the agenda build on a foundation of ongoing NIAID-supported TB research, which currently comprises more than 300 research projects worldwide.

Diagnosing, treating and controlling the spread of TB has become increasingly complicated because of the HIV/AIDS co-epidemic and the emergence of MDR and XDR TB, which threatens to set TB control efforts back to the pre-antibiotic era. According to NIAID Director Anthony S. Fauci, M.D., NIAID developed this TB research agenda to address MDR/XDR TB with appropriate urgency, while reaffirming the Institutes commitment to a robust program of research focused on all aspects of TB. NIAID is well prepared to foster the development of new TB diagnostics, drugs and vaccines, but given the realities of MDR/XDR TB, the research agenda outlines those areas that need additional attention to enable public health officials to more effectively combat all forms of tuberculosis, he says. He notes that the agenda is a Web-based living document that can be updated as scientific and public health needs and opportunities evolve.

NIAID collaborated with other government and non-government experts to prepare the MDR/XDR TB research agenda. In addition to its review by TB specialists in academia, advocacy groups, international organizations and other government agencies, the draft agenda was presented to the National Advisory Allergy and Infectious Diseases Council, NIAIDs main scientific advisory body.

The research agenda specifically describes six critical areas where additional investiga
'"/>

Contact: Jason Bardi
jbardi@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
6-Jun-2007


Page: 1 2

Related medicine news :

1. NIAID DNA vaccine for H5N1 avian influenza enters human trial
2. NIAID media availability: Examining genetic variability of malaria parasite offers insight
3. NIAID awards $4 million to develop anti-radiation treatments
4. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
5. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
6. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
7. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
8. NIAID media availability: Understanding influenza infection
9. NIAID researchers show how promising TB drug works
10. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
11. NIAID launches first Phase II trial of a global HIV/AIDS vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2019)... ... 14, 2019 , ... This past Saturday, volunteers from Bright Now! Dental ... the Parma Heights Day of Giving, where members of underserved communities were able to ... that partnered with the Smiles for Everyone Foundation. Some of these organizations ...
(Date:6/13/2019)... ... June 13, 2019 , ... Charm Sciences, Inc. is ... been accepted by the 2019 National Conference of Interstate Milk Shipments for screening ... The Charm BL30SEC test was validated by third party laboratories working in collaboration ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... proud to present the second annual Women|Future Conference and the advisory ... attendees to better position themselves and their organizations in tomorrow's marketplace. , The ...
(Date:6/13/2019)... ... ... Many people with back pain that radiates down their legs know they’re ... and so are its treatments, according to Kaliq Chang, MD, double board-certified in interventional ... is commonly used to describe nerve-like pain traveling down the legs, often from compression ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... manufacturing (AM)-enabled tissue fabrication, patient-matched models and surgical guides, and prosthetics and ... to improve patient care. Children with birth defects, soldiers with cranial injuries, ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... 13, 2019 , ... Wellopp , a patient engagement ... recently announced the launch of its new community referral services team. , Wellopp ... local network of community resources focused on improving patients’ social determinants of health ...
(Date:6/13/2019)... WEST CONSHOHOCKEN, Pa. (PRWEB) , ... June 13, ... ... health services organization in the northeastern United States, today announced the appointment of ... will report directly to Chief Executive Officer Anthony Coletta, M.D., M.B.A. , ...
(Date:6/12/2019)... ... June 12, 2019 , ... Through their Sidewalk Angels ... to share the importance of protecting your entire family from Lyme and other tick-borne ... or how much fur we have. , Through this partnership SWA and GLA ...
Breaking Medicine Technology:
Cached News: